Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 2 (2005), Issue 5 (May)

1. Ovarian cancer metastasis: integrating insights from disparate model organisms.
   Nat Rev Cancer, 5(5): 355-66. [Abstract] [Full-text]
2. Recurrent mature cystic ovarian teratoma in adolescence: atypical case of the growing teratoma syndrome.
   Obstet Gynecol, 105(5): 1264-6. [Abstract] [Full-text]
3. The administration of chemotherapy in a patient with Charcot-Marie-Tooth and ovarian cancer.
   Gynecol Oncol, 97(2): 710-2. [Abstract] [Full-text]
4. Celiac disease presenting as a paraneoplastic syndrome in a patient with synchronous endometrial and ovarian cancers.
   Gynecol Oncol, 97(2): 704-6. [Abstract] [Full-text]
5. Epithelioid leiomyosarcoma of the ovary.
   Gynecol Oncol, 97(2): 697-9. [Abstract] [Full-text]
6. Management of an advanced ovarian cancer at 15 weeks of gestation: case report and literature review.
   Gynecol Oncol, 97(2): 693-6. [Abstract] [Full-text]
7. Ovarian dysgerminoma associated with Pseudo-Meigs' syndrome and functioning ovarian stroma: a case report.
   Gynecol Oncol, 97(2): 681-4. [Abstract] [Full-text]
8. Three-dimensional ultrasound to assess the response to treatment in gynecological malignancies.
   Gynecol Oncol, 97(2): 665-8. [Abstract] [Full-text]
9. Ovarian metastasis in a nulliparous woman with endometrial adenocarcinoma failing conservative hormonal treatment.
   Gynecol Oncol, 97(2): 652-5. [Abstract] [Full-text]
10. Futility: clinical decisions at the end-of-life in women with ovarian cancer.
    Gynecol Oncol, 97(2): 638-44. [Abstract] [Full-text]
11. Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk.
    Gynecol Oncol, 97(2): 543-9. [Abstract] [Full-text]
12. CA-125 AUC as a new prognostic factor for patients with ovarian cancer.
    Gynecol Oncol, 97(2): 529-34. [Abstract] [Full-text]
13. Ovarian cancer incidence in the United States, 1992-1999.
    Gynecol Oncol, 97(2): 519-23. [Abstract] [Full-text]
14. Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer.
    Gynecol Oncol, 97(2): 514-8. [Abstract] [Full-text]
15. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.
    Gynecol Oncol, 97(2): 501-7. [Abstract] [Full-text]
16. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors.
    Gynecol Oncol, 97(2): 489-96. [Abstract] [Full-text]
17. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer.
    Gynecol Oncol, 97(2): 476-82. [Abstract] [Full-text]
18. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Gynecol Oncol, 97(2): 457-67. [Abstract] [Full-text]
19. Development of ovarian cancer surgery quality indicators using a modified Delphi approach.
    Gynecol Oncol, 97(2): 446-56. [Abstract] [Full-text]
20. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Gynecol Oncol, 97(2): 436-41. [Abstract] [Full-text]
21. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells.
    Gynecol Oncol, 97(2): 413-21. [Abstract] [Full-text]
22. Chemotherapy-induced changes of CA 125 in patients with epithelial ovarian cancer.
    Gynecol Oncol, 97(2): 410-2. [Abstract] [Full-text]
23. Inhibitory effects of herbal drugs on the growth of human ovarian cancer cell lines through the induction of apoptosis.
    Gynecol Oncol, 97(2): 405-9. [Abstract] [Full-text]
24. Lymphatic metastasis in epithelial ovarian carcinoma with respect to clinicopathological variables.
    Gynecol Oncol, 97(2): 400-4. [Abstract] [Full-text]
25. The accuracy of frozen section (intraoperative consultation) in the diagnosis of ovarian masses.
    Gynecol Oncol, 97(2): 395-9. [Abstract] [Full-text]
26. Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors.
    Gynecol Oncol, 97(2): 379-86. [Abstract] [Full-text]
27. Effusion cytodiagnosis of carcinosarcoma derived from the female genital tract: immunohistochemical features of MMP-7 and Ki-67 and immunofluorescence double staining analyses of eight cases.
    Gynecol Oncol, 97(2): 323-9. [Abstract] [Full-text]
28. Hysterectomy with or without unilateral oophorectomy and risk of ovarian cancer.
    Gynecol Oncol, 97(2): 318-22. [Abstract] [Full-text]
29. The role of neoadjuvant chemotherapy in the treatment of advanced ovarian cancer.
    Oncology, 68(1): 64-70. [Abstract] [Full-text]
30. Atypical Meigs' syndrome in a neonate with ovarian torsion associated with an ovarian dermoid cyst.
    Pediatr Surg Int, 21(5): 407-9. [Abstract] [Full-text]
31. Antiproliferative effect of beta-elemene in chemoresistant ovarian carcinoma cells is mediated through arrest of the cell cycle at the G2-M phase.
    Cell Mol Life Sci, 62(7): 894-904. [Abstract] [Full-text]
32. Hepatic resection of giant metastatic tumor from clear cell carcinoma of the ovary.
    J Hepatobiliary Pancreat Surg, 12(2): 155-8. [Abstract] [Full-text]
33. Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer.
    Cancer Res, 65(9): 3735-44. [Abstract] [Full-text]
34. Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis.
    Cancer Res, 65(9): 3726-34. [Abstract] [Full-text]
35. Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas.
    Clin Cancer Res, 11(9): 3225-32. [Abstract] [Full-text]
36. Serum lipids concentration in women with benign and malignant ovarian tumours.
    Eur J Obstet Gynecol Reprod Biol, 120(1): 87-90. [Abstract] [Full-text]
37. Ovarian ependymoma.
    APMIS, 113(4): 301-3. [Abstract] [Full-text]
38. Expression of lysophosphatidic acid acyltransferase beta (LPAAT-beta) in ovarian carcinoma: correlation with tumour grading and prognosis.
    Br J Cancer, 92(9): 1729-36. [Abstract] [Full-text]
39. Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer.
    Br J Cancer, 92(9): 1737-45. [Abstract] [Full-text]
40. Diagnostic challenge of secondary (metastatic) ovarian tumors simulating primary endometrioid and mucinous neoplasms.
    Pathol Int, 55(5): 231-43. [Abstract] [Full-text]
41. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract.
    Nat Med, 11(5): 531-7. [Abstract] [Full-text]
42. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy.
    Cancer Chemother Pharmacol, 56(1): 91-6. [Abstract] [Full-text]
43. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation.
    Exp Cell Res, 306(1): 128-41. [Abstract] [Full-text]
44. Prevalence of five previously reported and recurrent BRCA1 genetic rearrangement mutations in 20,000 patients from hereditary breast/ovarian cancer families.
    Genes Chromosomes Cancer, 43(3): 309-13. [Abstract] [Full-text]
45. Non-Hodgkin's lymphoma presenting as advanced ovarian cancer--a case report and review of literature.
    Int J Gynecol Cancer, 15(3): 554-7. [Abstract] [Full-text]
46. Carcinosarcoma-like mural nodule in intestinal-type mucinous ovarian of borderline malignancy: a case report.
    Int J Gynecol Cancer, 15(3): 549-53. [Abstract] [Full-text]
47. Is aromatase cytochrome P450 involved in the pathogenesis of endometrioid endometrial cancer?
    Int J Gynecol Cancer, 15(3): 529-36. [Abstract] [Full-text]
48. Ultrastructure alterations in adriamycin-resistant and cisplatin-resistant human ovarian cancer cell lines exposed to nonlethal ultrasound.
    Int J Gynecol Cancer, 15(3): 462-7. [Abstract] [Full-text]
49. Diagnostic approach using the expression profiling of the P53 tumor suppressor gene and its related proteins in ovarian epithelial tumors.
    Int J Gynecol Cancer, 15(3): 453-61. [Abstract] [Full-text]
50. Chemosensitivity testing of ovarian cancer using the histoculture drug response assay: sensitivity to cisplatin and clinical response.
    Int J Gynecol Cancer, 15(3): 445-52. [Abstract] [Full-text]
51. Quantitative biochemical analysis of lactate dehydrogenase in human ovarian tissues: correlation with tumor grade.
    Int J Gynecol Cancer, 15(3): 438-44. [Abstract] [Full-text]
52. Clear-cell cancer of the ovary-is it chemosensitive?
    Int J Gynecol Cancer, 15(3): 432-7. [Abstract] [Full-text]
53. Preliminary toxicity analysis of intraperitoneal carboplatin in combination with intravenous paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube.
    Int J Gynecol Cancer, 15(3): 426-31. [Abstract] [Full-text]
54. Hormone replacement therapy on ovarian and uterine cancer risk and cancer survivors: how shall we do no harm?
    Int J Gynecol Cancer, 15(3): 420-5. [Abstract] [Full-text]
55. A case control study of glycoprotein status in ovarian carcinoma.
    Clin Biochem, 38(6): 535-9. [Abstract] [Full-text]
56. A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance.
    Proc Natl Acad Sci U S A, 102(19): 6936-41. [Abstract] [Full-text]
57. Ovarian serous cystadenoma with mural nodules of genital rhabdomyoma.
    Hum Pathol, 36(4): 433-5. [Abstract] [Full-text]
58. Gonadoblastomas in 5 patients with 46,XY gonadal dysgenesis.
    Exp Clin Endocrinol Diabetes, 113(4): 231-5. [Abstract] [Full-text]
59. The decision evaluation scales.
    Patient Educ Couns, 57(3): 286-93. [Abstract] [Full-text]
60. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients.
    Clin Cancer Res, 11(10): 3814-20. [Abstract] [Full-text]
61. The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer.
    Clin Cancer Res, 11(10): 3733-42. [Abstract] [Full-text]
62. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.
    Clin Cancer Res, 11(10): 3686-96. [Abstract] [Full-text]
63. Identification of novel targeting peptides for human ovarian cancer cells using "one-bead one-compound" combinatorial libraries.
    Mol Cancer Ther, 4(5): 806-13. [Abstract] [Full-text]
64. Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy.
    Mol Cancer Ther, 4(5): 715-25. [Abstract] [Full-text]
65. Ovarian cancer identification based on dimensionality reduction for high-throughput mass spectrometry data.
    Bioinformatics, 21(10): 2200-9. [Abstract] [Full-text]
66. Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin.
    Mol Pharmacol, 67(6): 1852-60. [Abstract] [Full-text]
67. Epigenetic silencing of the imprinted gene ZAC by DNA methylation is an early event in the progression of human ovarian cancer.
    Int J Cancer, 115(5): 690-700. [Abstract] [Full-text]
68. Collateral missing value imputation: a new robust missing value estimation algorithm for microarray data.
    Bioinformatics, 21(10): 2417-23. [Abstract] [Full-text]
69. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays.
    Int J Cancer, 115(5): 783-9. [Abstract] [Full-text]
70. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin.
    Cancer Res, 65(10): 4334-42. [Abstract] [Full-text]
71. High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors.
    Cancer Genet Cytogenet, 159(2): 114-22. [Abstract] [Full-text]
72. Inflammation-associated gene expression is altered between normal human ovarian surface epithelial cells and cell lines derived from ovarian adenocarcinomas.
    Br J Cancer, 92(10): 1927-33. [Abstract] [Full-text]
73. The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers.
    Am J Obstet Gynecol, 192(5): 1614-9. [Abstract] [Full-text]
74. Randomized comparison of group versus individual genetic education and counseling for familial breast and/or ovarian cancer.
    J Clin Oncol, 23(15): 3455-64. [Abstract] [Full-text]
75. beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients.
    Eur J Cancer, 41(8): 1127-34. [Abstract] [Full-text]
76. Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma.
    Cancer, 103(11): 2313-9. [Abstract] [Full-text]
77. Treated ovarian cancer: MR imaging, laparotomy reassessment, and serum CA-125 values compared with clinical outcome at 1 year.
    Radiology, 235(3): 918-26. [Abstract] [Full-text]
78. Serum protein markers for early detection of ovarian cancer.
    Proc Natl Acad Sci U S A, 102(21): 7677-82. [Abstract] [Full-text]
79. Survival analysis in advanced epithelial ovarian carcinoma in relation to proliferative index of MIB-1 immunostaining.
    J Obstet Gynaecol Res, 31(3): 268-76. [Abstract] [Full-text]
80. Leiomyoma of the ovary presenting with Meigs' syndrome.
    J Obstet Gynaecol Res, 31(3): 257-62. [Abstract] [Full-text]
81. Gonadoblastoma in Turner syndrome and Y-chromosome-derived material.
    Am J Med Genet A, 135(2): 150-4. [Abstract] [Full-text]
82. Laparoscopic surgery in 12 cases of adnexal disease occurring in girls aged 15 years or younger.
    J Minim Invasive Gynecol, 12(3): 234-40. [Abstract] [Full-text]
83. VEGF and its receptors (flt-1 and KDR/flk-1) as prognostic indicators in endometrial carcinoma.
    Tumour Biol, 26(2): 81-7. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.